Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) EPS (Weighted Average and Diluted) (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.25 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 41.86% to -$0.25 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.14 through Dec 2025, up 91.41% year-over-year, with the annual reading at -$0.14 for FY2025, 91.3% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.25 at Century Therapeutics, up from -$0.4 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.89 in Q1 2025, with the low at -$1.24 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.44, with a median of -$0.49 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 297.78% in 2025, while the deepest fall reached 8.11% in 2025.
  • Over 4 years, EPS (Weighted Average and Diluted) stood at -$1.24 in 2022, then soared by 47.58% to -$0.65 in 2023, then surged by 33.85% to -$0.43 in 2024, then surged by 41.86% to -$0.25 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.25, -$0.4, and -$0.38 for Q4 2025, Q3 2025, and Q2 2025 respectively.